AUSTIN, Texas, Aug. 13, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative,...
Meeting adjourned only with respect to reverse stock split proposal until September 8, 2022SAN DIEGO, Aug. 12, 2022 (GLOBE NEWSWIRE)...
Tampa, Aug. 12, 2022 (GLOBE NEWSWIRE) -- Turning Point of Tampa, a leading treatment provider in Tampa, Florida is pleased...
Philips intravascular ultrasound (IVUS) - 1 Philips intravascular ultrasound (IVUS) - 2 August 12, 2022 First-ever global consensus guidance published...
Revenue in USD Revenue In USD Adjusted EBITDA & Operating Income (Loss) in USD $ Adjusted EBITDA & Operating Income...
Rosh Pinna, Israel, Aug. 12, 2022 (GLOBE NEWSWIRE) -- (“IR-MED or the “Company”) (OTCQB:IRME), an innovative medical device company, developing...
Conference call begins at 11:00 a.m. Eastern time today WOBURN, Mass., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq:...
Orphan designation provides potential for up to 10-year market exclusivity in the EU upon regulatory approvalGENEVA, Switzerland and NEWTON, Mass.,...
ROSELAND, N.J., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments,...
Additional data from the lead-in of PNT2002's SPLASH trial on track for fall 2022 release PNT6555, the lead of the...
CARLSBAD, Calif., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for...
Positive interim results from registration-enabling study of cosibelimab in locally advanced cutaneous squamous cell carcinoma announced in June 2022 Successful...
BRIDGEWATER, N.J., Aug. 12, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company...
Paltusotine’s Phase 3 PATHFNDR Program in Acromegaly and Phase 2 Program in Carcinoid Syndrome Remain on Track for Top-Line Data...
BOSTON, Aug. 12, 2022 (GLOBE NEWSWIRE) -- PepGen Inc. (“PepGen”), a clinical-stage biotechnology company advancing the next generation of oligonucleotide...
Financial Highlights: Second Quarter 2022 Consolidated Net Revenues Rose to $6,910,386 from $404,676 Compared to First Quarter 2022Records $3,881,620 Net...
FOSTER CITY, Calif., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage...
Patent extends protection for SciSparc’s novel compounds and methods already granted in the U.S., Australia and Japan TEL AVIV, Israel,...
Neurotechnology solution gains vital certification needed for EU expansion Palo Alto, CA – (August 10, 2022) – SyncThink, a next generation...
New capabilities within H1’s HCP Universe platform empower corporate Medical Affairs and MSL teams to act faster and more effectively...